TRP_1170x120_12-19-19

GlaxoSmithKline

GSK Consumer Healthcare teams with Paula Abdul to launch Voltaren Arthritis Pain Gel

GSK Consumer Healthcare teams with Paula Abdul to launch Voltaren Arthritis Pain Gel

WARREN, N.J. — GlaxoSmithKline announced that Voltaren Arthritis Pain Gel (diclofenac sodium topical gel, 1% (NSAID) arthritis pain reliever) recently became available over-the-counter (O-T-C) online and in stores nationwide, providing the over 30 million osteoarthritis patients across the country broader access to a leading pain relief option. To launch the O-T-C offering, Voltaren is teaming

FDA approves GSK’s Voltaren Arthritis Pain for O-T-C use

FDA approves GSK’s Voltaren Arthritis Pain for O-T-C use

WARREN, N.J. — GlaxoSmithKline announced Tuesday that the U.S. Food and Drug Administration (FDA) has approved Voltaren Arthritis Pain (diclofenac sodium topical gel, 1% (NSAID)- arthritis pain reliever) as an over-the-counter (O-T-C) product for the temporary relief of arthritis pain in the hand, wrist, elbow, foot, ankle or knee in adults (18 years and older).  With

Drugs and medical equipment see global gains

Drugs and medical equipment see global gains

Growth of the global pharmaceuticals and medical equipment industry gathered pace in 2018, with the Asia Pacific region and Western Europe registering the most substantial increases over the previous year, 8.2% and 8.1%, respectively, according to Euromonitor International. Meanwhile, a deteriorating trade environment in the light of pending Brexit and U.S.-China trade disputes, as well

GlaxoSmithKline, Pfizer close joint venture

GlaxoSmithKline, Pfizer close joint venture

WARREN, N.J. — GlaxoSmithKline said Thursday that it has closed a previously announced joint venture deal with Pfizer Inc. that will combine their respective consumer healthcare businesses. The move will create the world’s largest supplier of over-the-counter medications. The joint venture company will operate as GSK Consumer Healthcare. Pfizer owns a 32% equity stake in

Prices boosted on hundreds of drugs

Prices boosted on hundreds of drugs

NEW YORK — Drugmakers are increasing the price of hundreds of drugs by an average of more than 6%, according to a new analysis by Rx Savings Solutions. With pressure on the pharmaceutical industry to hold down prices mounting, many of the increases are relatively small. But some generics are seeing steep hikes, and overall

GSK, Pfizer create O-T-C giant

GSK, Pfizer create O-T-C giant

NEW YORK — GlaxoSmithKline Plc and Pfizer Inc. have struck a deal that will create the largest over-the-counter drug company in the world. GSK paved the way for a split into two companies, agreeing to create the consumer-health joint venture with Pfizer. GSK, according to the deal, with retain a 68% controlling stake in the new

Camber Pharmaceuticals launches generic Mepron

Camber Pharmaceuticals launches generic Mepron

Piscataway, N.J.– Camber Pharmaceuticals is pleased to announce the addition of atovaquone oral solution to our growing portfolio of products. Atovaquone oral solution is the generic version of Mepron from GlaxoSmithKline and is used to treat or prevent pneumonia caused by a fungal infection called Pneumocystis carinii. Atovaquone oral solution is available in 750 mg/5 mL

Iain Mackay appointed CFO at GSK

Iain Mackay appointed CFO at GSK

 LONDON — GlaxoSmithKline (GSK) announced that Iain Mackay has been appointed GSK’s next chief financial officer (CFO). He has also been appointed as an Executive Director to the GSK board. Mackay will join the company on January 14, 2019.  Mackay joins GSK from the global bank HSBC, where he has been Group Finance Director for

GSK to buy out Novartis in consumer health joint venture

GSK to buy out Novartis in consumer health joint venture

LONDON and BASEL, Switzerland — GlaxoSmithKline plc plans to buy Novartis’ 36.5% stake in their consumer health care joint venture for $13 billion. Under the agreement announced Tuesday, Novartis’ shares in the joint venture will be canceled, and the joint venture will pay the buyout price to Novartis. GSK has entered into a committed facilities agreement to

Ex-GSK CEO Andrew Witty to take helm at Optum

Ex-GSK CEO Andrew Witty to take helm at Optum

MINNEAPOLIS — Former GlaxoSmithKline plc chief executive officer Sir Andrew Witty has been named CEO of Optum, the health services, technology and pharmacy benefits management unit of health insurance giant UnitedHealth Group. Plans call for Witty to start as Optum CEO on July 1. He takes over from Larry Renfro, vice chair of UnitedHealth Group, who has

Mayne Pharma releases Fabior, Sorilux foam

Mayne Pharma releases Fabior, Sorilux foam

GREENVILLE, N.C. — Mayne Pharma Inc. has rolled out Fabior Foam 0.1%, an acne treatment, and Sorilux Foam 0.005%, a psoriasis treatment, in the United States. Launched by the Mayne Pharma Specialty Brands division, Fabior and Sorilux foam previously were marketed by GlaxoSmithKline. Mayne acquired the two products in August 2016. Mayne said Fabior and

HDA eyes GTIN coding system for pharma supply chain

HDA eyes GTIN coding system for pharma supply chain

ARLINGTON, Va. — Later next year, the Healthcare Distribution Alliance (HDA) plans to launch a service to aid the adoption of a Global Trade Item Number (GTIN) coding system across the pharmaceutical supply chain. HDA said Monday that the GTIN Repository Service, prompted by the enactment of the Drug Supply Chain Security Act (DSCSA), will

GSK’s FluLaval gains expanded age indication

GSK’s FluLaval gains expanded age indication

PHILADELPHIA —  GlaxoSmithKline has received approval from the Food and Drug Administration’s Center for Biologics Evaluation and Research expanding the indication for FluLaval Quadrivalent flu vaccine to include use in children ages 6 months and older. GSK said that previously FluLaval Quadrivalent was only cleared for active immunization against influenza A subtype viruses and type

GSK names McNamara as consumer health chief

GSK names McNamara as consumer health chief

LONDON — Brian McNamara has been promoted to chief executive officer of GlaxoSmithKline plc’s consumer health business. GSK said McNamara assumes the GSK Consumer Healthcare CEO post and joins GSK’s corporate executive team effective immediately. He takes the reins from Emma Walmsley, who just over a week ago was named to succeed Sir Andrew Witty